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Available online 26 July 2016We describe the development and psychometric properties of a new, brief measure of smokers' knowledge of
lung cancer screening with low-dose computed tomography (LDCT). Content experts identiﬁed key facts
smokers should know in making an informed decision about lung cancer screening. Sample questions were
drafted and iteratively reﬁned based on feedback from content experts and cognitive testing with ten smokers.
The resulting 16-item knowledge measure was completed by 108 heavy smokers in Houston, Texas, recruited
from 12/2014 to 09/2015. Item difﬁculty, item discrimination, internal consistency and test-retest reliability
were assessed. Group differences based upon education levels and smoking history were explored. Several
items were dropped due to ceiling effects or overlapping constructs, resulting in a 12-item knowledge measure.
Additional items with high item uncertainty were retained because of their importance in informed decision
making about lung cancer screening. Internal consistency reliability of the ﬁnal scale was acceptable (KR-
20= 0.66) and test-retest reliability of the overall scale was 0.84 (intraclass correlation). Knowledge scores dif-
fered across education levels (F= 3.36, p= 0.04), while no differences were observed between current and for-
mer smokers (F = 1.43, p = 0.24) or among participants who met or did not meet the 30-pack-year screening
eligibility criterion (F = 0.57, p = 0.45). The new measure provides a brief, valid and reliable indicator of
smokers' knowledge of key concepts central to making an informed decision about lung cancer screening with
LDCT, and can be part of a broader assessment of the quality of smokers' decision making about lung cancer
screening.






Shared decision making1. Introduction
Lung cancer is the leading cause of cancer deaths among men and
women in the United States (American Cancer Society, 2012). In 2011,
the ﬁndings from the National Lung Screening Trial showed a 20% re-
duction in lung cancer deaths among high-risk smokers randomized
to the low-dose computed tomography (LDCT) arm compared to
those in the chest X-ray arm (Aberle et al., 2011). Shortly thereafter,ices Research, The University of
301402, Houston, TX 77230-
. This is an open access article underthe United States Preventive Services Task Force (USPSTF) released an
updated statement endorsing lung cancer screening with LDCT, and
the Centers for Medicare & Medicaid Services (CMS) released the na-
tional coverage determination for Medicare coverage of lung cancer
screening with LDCT (Moyer, 2014; Centers for Medicare & Medicaid
Services, 2015). Thus, there is growing interest in implementing lung
cancer screening.
In its landmark beneﬁciary eligibility determination, CMS requires
that a patient counseling and shared decision-making visit with a pa-
tient decision aid precedes a preventive service (Moyer, 2014; Centers
for Medicare & Medicaid Services, 2015). The requirement for a shared
decision-making and patient counseling visit is due in part to recogni-
tion of the potential harms associated with lung cancer screening with
LDCT, including a high false positive rate, overdiagnosis, complicationsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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new cancers due to increased radiation exposure (Moyer, 2014; Bach
et al., 2012; Humphrey et al., 2013). Shared decision making is recom-
mended when the efﬁcacy of an available option, in this case lung can-
cer screening with LDCT, is not always certain and when there are
tradeoffs between beneﬁts and harms associated with the options.
CMS further calls for the use of patient decision aids as part of the shared
decision-making visit. Patient decision aids can support shared decision
making by presenting facts in a balanced manner and encouraging de-
liberation between patients and health care providers about the
tradeoffs (O'Connor et al., 1999). In light of the requirements by CMS
for lung cancer screening with LDCT, there is a clear need to have a reli-
able measure to assess the effectiveness of decision aids on patients'
knowledge.
This paper reports the development and psychometric properties of
a brief knowledge measure about lung cancer screening with LDCT for
use with smokers. This measure development study (ClinicalTrials.gov
ID: NCT02282969)was conducted as a precursor to a larger randomized
trial evaluating the effectiveness of a video-based patient decision aid
(Clinicaltrials.gov ID: NCT02286713).
2. Materials and methods
2.1. Knowledge item generation
In order to generate a pool of knowledge items, we asked tobacco
control experts, cancer prevention experts, and a diagnostic radiologist
to generate a list of key facts a patient should know in making an in-
formed decision about lung cancer screening with LDCT. We supple-
mented the expert-generated lists with information about lung cancer
screening presented in professional guidelines (Moyer, 2014; Wender
et al., 2013; National Comprehensive Cancer Network, 2011), patient
and physician fact sheets from professional organizations (American
Lung Association, 2012; American Society of Clinical Oncology, 2012;
American Cancer Society, 2013; U.S. Preventive Services Task Force,
2013; U.S. Preventive Services Task Force, 2014a; U.S. Preventive Ser-
vices Task Force, 2014b), the latest evidence synthesis from the
USPSTF (Humphrey et al., 2013), and knowledge items from a prior
study by the research team (Volk et al., 2014).
The resulting candidate set of 107 fact-based knowledge items (key
facts) was broadly grouped into 35 domains (e.g., mortality, incidence,
diagnosis, risk factors). The listwas reviewed and sorted by the research
team, and redundant domains and key factswere collapsed or removed.
The resulting 16 domainswith 29 key facts were edited for literacy level
in advance of cognitive testing and entered into an online survey. Med-
ical content experts (N = 3), from cancer prevention, community on-
cology practice, and radiology, and research team members rated each
item as “essential,” “optional,” or “not necessary” for patients to make
an informed decision. From these ratings, 13 domains represented in
16 key facts about lung cancer screening were included in the knowl-
edge measure and evaluated for face validity.
For cognitive testing, participants were recruited from the Tobacco
Treatment Program (TTP) at The University of TexasMDAnderson Can-
cer Center. Eligible participants were current or former smokers 55 to
80 years oldwith no prior history of lung cancer. After obtainingwritten
consent, research assistants conducted cognitive testing with 10 partic-
ipants using a “thinking-out-loud” technique, where the participant is
asked a series of questions to understand his or her interpretation of
what each item is asking and what the response choices mean
(Dillman, 1978). We iteratively reﬁned the measure (items and re-
sponses) based upon cognitive testing results.
2.2. Data collection procedures
Data were collected between December 2014, and September 2015.
A multipronged strategy was used to recruit participants, includingcontacting patients from the TTP at MD Anderson, placing advertise-
ments in local newspapers, and relying on referrals from existing partic-
ipants in the study. Eligible participants included English-speakingmen
andwomen ages 55 to 80 yearswhowere either current smokers or had
quit within the past 15 years. Individuals who had been diagnosed with
lung cancer were ineligible. These criteria mirrored USPSTF criteria for
lung cancer screening eligibility, except pack-year smoking history. Al-
though pack-year smoking history was not an eligibility criterion for
our study, we did assess pack-year smoking history and compared re-
sults for participants who did or did not have a minimum of a 30
pack-year smoking history.
After consenting to the study, participants completed a baseline
questionnaire, and again completed a follow-up questionnaire one
month later. The one month time lag was selected, instead of the stan-
dard 10 days to 2 weeks interval, to minimize priming effects on the
participants' knowledge of lung cancer screening. The order of the
knowledge questions was randomized at the follow-up. Participants
also completed demographic questions at baseline. This study was ap-
proved by MD Anderson's Institutional Review Board.
2.3. Analysis
We tested the psychometric properties of the knowledge measure,
including item difﬁculty, item discrimination, reliability, and validity.
Not all subjects completed the follow-upquestionnaire. Sensitivity anal-
ysis of data from the participantswhoonly completed the baseline com-
pared to participants who had completed baseline and follow-up
revealed that the item characteristics did not differ signiﬁcantly. Data
analysis was conducted with SPSS.
2.3.1. Item difﬁculty and uncertainty
Item difﬁculty was determined by examining the proportion of cor-
rect responses. Generally, items with 50% correct responses tend to in-
crease the reliability of a multi-item measure (Crocker & Algina,
1986), although highly difﬁcult items may be retained in a measure if
they assess constructs potentially amenable to educational interven-
tions. Item uncertainty was deﬁned as the proportion of “I don't
know” responses.
2.3.2. Index of discrimination
The index of discrimination was used to assess the validity of the
items in discriminating among high and low performers on the scale.
The index of discrimination is the difference between the proportion
of correct responses of participants in the upper and lower 25th percen-
tiles. Traditionally, itemswith an index of discrimination of 40% are con-
sidered acceptable, and those with an index less than 20% are
considered inadequate (Ebel, 1965).
2.3.3. Reliability
We assessed the reliability of the overall knowledge measure using
the Kuder-Richardson 20 (KR-20) formula, an indicator of internal con-
sistency reliability for scales with dichotomous responses (i.e., correct
or incorrect responses) (Cronbach, 1951; Kuder & Richardson, 1937).
Characteristics of the individual items were examined using item-total
correlations, and internal consistency of the overall scale if the item
was deleted (alpha if item deleted). Test-retest reliability of the individ-
ual itemswas calculatedwith kappa coefﬁcients, and test-retest reliabil-
ity of the overall knowledge measure was estimated by the intraclass
correlation.
2.3.4. Differences between groups
One-way analysis of variancewas used to explore group differences.
It was expected that knowledge would differ between education levels,
which would reﬂect concurrent validity, a type of criterion validity. It is
expected that those with higher education (graduated high school/GED
or less, some college/trade school, graduated college or more) would
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was conducted to explore whether current smokers and participants
who met eligibility criteria for lung cancer screening had different
knowledge scores.
2.3.5. Item selection
We considered the performance of the scale items across a number
of indicators in making decisions about which items to retain or delete.
Decisions to retain or delete an item were not based on a single indica-
tor. Instead, we sought to retain items that had a potential to 1) be re-
sponsive to an intervention, 2) discriminate between high and low
performers, and 3) represented a necessary fact to make an informed
decision. For example, a difﬁculty itemmay be kept if the level of uncer-
tainty was moderate to high, indicating that the item has the potential
to be responsive to an intervention. Generally, itemswith a ceiling effect
would be deleted, unless they represented an essential fact and there




The participants' ages ranged from 55 to 77 years, and slightly more
than half were female (Table 1). The majority of participants were
White, not Hispanic, and had more than a high school degree. There
were no statistically signiﬁcant differences between those who did
and did not complete the follow-up questionnaire, one month after
baseline.
3.2. Item characteristics
Item characteristics of the initial 16-item measure are given in
Table 2. The item difﬁculty ranged from 1.7% to 88.3% correct, and
item uncertainty ranged from 2.5% to 66.7%. The two items assessing
knowledge about the association between smoking and lung cancer
(Items # 2 and #3) had very high proportions of correct responses.Table 1
Characteristics of the subjects.
Baseline (n, %)
N = 120
1 month (n, %)
N = 108
p-valuea
Age (mean, sd) 63.5 (5.9) 63.59 (6.0) 0.94
Gender 0.28
Male 57 (47.5) 50 (46.3)
Female 63 (52.5) 58 (53.7)
Race 0.91
Asian/Paciﬁc Islander 3 (2.5) 3 (2.8)
Black or African-American 29 (24.2) 26 (24.1)
White 85 (70.8) 76 (70.4)
Not speciﬁed 2 (1.7) 2 (1.9)
Refused to answer 1 (0.8) 1 (0.9)
Ethnicity 0.64
Hispanic 6 (5.0) 5 (4.6)
Not Hispanic 113 (94.2) 102 (94.4)
Education 0.22
Less than high school 3 (2.5) 3 (2.8)
Graduated high school/GED 17 (16.7) 17 (15.7)
Some college/trade school 41 (40.8) 42 (38.9)
Graduated college or more 46 (40.0) 46 (42.6)
Current smoker 61 (50.8) 53 (49.1) 0.38
Years smoked cigarettes (mean, sd) 40.3 (16.8) 37.2 (12.0) 0.08
Avg. cigarettes smoked per day (mean, sd) 18.09 (9.3) 18.37 (9.4) 0.62
Pack-year history (mean, sd) 36.5 (23.3) 36.8 (23.8) 0.57
Abbreviations: sd= standard deviation, GED=general educational development, Avg.=
average
All data were collected from 12/2014 to 09/2015 in Houston, TX.
a The p-values are based upon one-way ANOVA for continuous variables and chi-square
tests comparing those who completed baseline and follow-up and those who did not.Interestingly, both items had low levels of uncertainty (10.8% and
2.5%), suggesting that participants were conﬁdent in their responses.
These items were not included in the ﬁnal measure. We incorporated
two items on the predictive value of screening (Items #7 and #8). Al-
though only a few participants answered Item #7 correctly (2.5%), we
felt that it would be more responsive to an intervention than Item #8.
For the ﬁnal measure, Item #7 was retained and Item #8 was dropped.
Several items were deemed very difﬁcult, with only a small propor-
tion of participants responding correctly. Only a few participants chose
all three correct responses for the multi-choice screening eligibility
question, “When should someone stop being screened for lung cancer?”
(Item #5). We therefore considered this item as being “correct” if the
subject endorsed any of the correct responses without also selecting “I
don't know.”With thismodiﬁcation, theproportion of correct responses
increased from 4.2% to 47.6%, and Item #5 with the alternative scoring
system was retained. Item #6 (“Should all current and former smokers
be screened for lung cancer?”) appeared to reﬂect more of a personal
belief given that very few people were uncertain about their response
(5.8%), despite 91.7% being incorrect. Therefore, Item #6 was dropped
from the ﬁnal measure. Knowledge of the magnitude of the mortality
beneﬁt of lung cancer screening with LDCT (Item #13) was poor. How-
ever, we retained this item because it was viewed as essential by the
content experts and should be amendable to educational interventions.
Examination of the discrimination between lower and higher per-
formers generally supported the ﬁndings for item difﬁculty and uncer-
tainty. The index of discrimination for Items #7 (predictive value of
screening) and #13 (mortality beneﬁt of screening) was low, but be-
cause of high item uncertainty and importance assigned by the content
experts these items were retained.
3.3. Reliability
The alpha if item deleted remained fairly stable ranging from 0.65 to
0.71, and suggested that none of the items detracted from the overall
scale's reliability. The test-retest reliability estimates ranged from 0.13
to 0.66. For the overall scale, the KR-20 was 0.69, suggesting acceptable
internal consistency.
After dropping the poor performing or redundant items, the
resulting 12-item knowledge measure (Table 3) had a similar internal
consistency as the 16-item knowledge measure (KR-20 = 0.66) and a
high test-retest reliability (ICC = 0.84). The mean score at baseline
was 4.59 with a standard deviation of 2.38 (using the modiﬁed scoring
for Item #5). The mean knowledge score was statistically different
across education levels (high school or less: mean ± standard devia-
tion = 3.57 ± 1.80; some college: 4.58 ± 2.41; college or more
5.10 ± 2.48; F = 3.36, p = 0.04). Knowledge scores did not differ be-
tween current and former smokers (current smoker: 4.31 ± 2.53; for-
mer smoker: 4.91 ± 2.18; F = 1.43, p = 0.24) nor participants who
met or did not meet the 30 pack-year lung cancer screening eligibility
criterion (met criterion: 4.75 ± 2.33; did not meet criterion: 4.41 ±
2.42; F = 0.57, p = 0.45).
4. Discussion
We developed a brief, self-report measure of smokers' understand-
ing of key concepts central to making an informed decision about lung
cancer screening with LDCT. A careful development process was used
to identify key facts smokers should understand in making an informed
screening decision, test the items for clarity and face validity, and select
a ﬁnal set of items with acceptable item characteristics and reliability.
The processwasmultidisciplinary and patients/smokers played a signif-
icant role in reﬁning the measure.
Sepucha and colleagues (Sepucha et al., 2014; Sepucha et al., 2013;
Sepucha et al., 2011; Sepucha et al., 2008; Sepucha et al., 2007) have ar-
gued that high quality decisions are those where the patient under-
stands the options and associated harms and beneﬁts, and makes
Table 2



















20.8% 50.8% 23.4% 0.12 0.70 0.29
2. Is smoking the leading cause of lung cancer?a Risk factors, smoking 84.2% 10.8% 40.0% 0.23 0.69 0.33
3. The most important thing smokers can do to lower their risk of
lung cancer is to…a
Risk reduction, smoking 88.3% 2.5% 7.4% -0.01 0.71 0.13
4. Where does lung cancer rank as a cause of cancer death in
the US?
Risk, cause of death 25.8% 45.0% 53.1% 0.30 0.68 0.41
5. When should someone stop being screened for lung cancer?
(Check all that apply)
Screening eligibility 47.5% 41.7% 52.6% 0.25 0.69 0.44
6. Should all current and former smokers be screened for lung
cancer?a
Screening eligibility 2.5% 5.8% 2.9% 0.10 0.69 0.66




2.5% 66.7% 2.9% 0.07 0.70 0.38
8. Does an abnormal CT scan mean a person has lung cancer?a Predictive value of
screening
63.3% 35.0% 75.4% 0.49 0.65 0.41




37.5% 50.8% 67.4% 0.40 0.66 0.36
10. Can a CT scan miss a tumor in your lungs? Screening accuracy,
false negatives
52.5% 37.5% 68.0% 0.38 0.67 0.49




57.5% 30.0% 83.4% 0.52 0.65 0.45
12. Without screening, is lung cancer often found at a later stage
when cure is less likely?
Screening beneﬁt,
mortality
72.5% 24.2% 52.6% 0.32 0.68 0.22
13. How much does screening for lung cancer with a CT scan
lower your chances of dying from lung cancer?
Screening beneﬁt,
mortality reduction
1.7% 59.2% -1.1% 0.00 0.70 0.20
14. Can a CT scan ﬁnd lung disease that is not cancer? Screening, secondary
ﬁndings
70.0% 29.2% 77.1% 0.52 0.65 0.57
15. Can a CT scan ﬁnd heart disease? Screening, secondary
ﬁndings
44.2% 50.0% 64.0% 0.29 0.68 0.28
16. Is radiation exposure one of the harms of lung cancer
screening?
Screening risks 29.2% 42.5% 56.0% 0.33 0.67 0.39
Bolded items were included in the ﬁnal lung cancer screening knowledge measure.
Abbreviations: CT = Computed tomography, α= alpha. All data were collected from 12/2014 to 09/2015 in Houston, TX.
a Items were dropped from ﬁnal lung cancer screening knowledge measure.
b Item difﬁculty is the percentage correct responses.
c Item uncertainty is the percentage of “I don't know” responses.
d The index of discrimination is the difference between percentage of respondents with correct responses for an item among those who scored in the upper versus lower quartiles of
correct responses to the full scale. Items with an index of discrimination greater than 40% are considered acceptable for discrimination, and those with an index less than 20% are consid-
ered inadequate.
e Item-Total Correlation is the correlation between the response on an individual question and the overall score on the survey.
f α if item deleted represents the internal consistency of the scale without that item.
g Kappa coefﬁcients are reported for baseline and 1-month, and represent average intercorrelation of items with dichotomous responses.
354 L.M. Lowenstein et al. / Preventive Medicine Reports 4 (2016) 351–356decisions consistent with one's values. The brief knowledge measure
developed in this study can provide an indicator of patients' compre-
hension of these key facts, and be part of a broader assessment of
decision-making quality about lung cancer screening.
It is noteworthy that participants in the study had difﬁculty with the
twoquestions about eligibility criteria for screening. One question asked
whether all current and former smokers should be screened, and over
90% of participants answered afﬁrmatively. This may, in part, represent
patients' enthusiasm for cancer early detection in general (Schwartz
et al., 2004) and wanting all smokers to be screened for lung cancer re-
gardless of their smoking behavior. This item may have captured the
concept more accurately if it was framed as “According to the guide-
lines, should all current and former smokers be screened for lung can-
cer?” The question assessing criteria for discontinuing lung cancer
screening was challenging as well, which may be due in part to the
“check all that apply” response format. Yet, this concept is important be-
cause of concerns about “eligibility slippage”where patients not meet-
ing all requirements for lung cancer screening may receive services
(Centers for Medicare & Medicaid Services, 2014), and we therefore
retained this item in the ﬁnal measure. Additional item reﬁnement
may be needed to better assess patients' understanding of exclusion
criteria for screening.
Ceiling effects were observed for two items related to knowledge
about the role of smoking in lung cancer. This ﬁnding is not surprisinggiven long-standing public awareness campaigns focused on reducing
lung cancer deaths through tobacco cessation. Two additional items
showed high difﬁculty and uncertainty. The predictive value of an ab-
normal CT scan was poorly understood. Many participants felt that an
abnormal ﬁnding was likely lung cancer, and few participants knew
the magnitude of the beneﬁt of lung cancer screening in reducing lung
cancer deaths. We argue that these items represent central facts re-
quired in making an informed screening decision and should be
retained. They may also be highly amenable to educational interven-
tions targeted to patients, where large gains in knowledge might be
expected.
This studyhas several limitations. Overall, the sample included ama-
jority of participants with at least some college education, while nation-
al statistics suggest a higher smoking prevalence among people with a
high school education or less (Centers for Disease Control and
Prevention, 2010; Centers for Disease Control and Prevention, 2004).
The responsiveness of the measure to educational interventions was
not assessed in this study and will be important to demonstrate in fu-
ture research. We included in the sample some individuals who would
not meet screening eligibility criteria based on their smoking history.
However, the knowledge scores did not differ for smokers meeting the
30 pack-year smoking threshold compared to those who did not. The
“select all that apply” response structure for the item on when to stop
screeningmay have been too difﬁcult. Further testing would be needed
Table 3
Final 12-item lung cancer screening knowledge measure.
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domain. However, we did propose an alternative scoring method
which improved the psychometric properties of this item.
The brief knowledgemeasure developed in this study can be used to
characterize the degree of awareness of facts about lung cancer and lung
cancer screening in speciﬁc populations, set a baseline for intervention
studies, and serve as an outcomemeasure for educational interventions.
Future researchmight consider identifying an abbreviated set of core in-
dicators that can be used in the clinical setting to identify participants at
greatest need for educational interventions and decision support about
lung cancer screening.
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